PIK3CA Mutation Detection
Ordering Recommendation
• Predicts response to anti-EGFR and AKT/mTOR pathway therapies in a variety of malignancies (eg, colorectal, ovarian, and breast cancer).
• Detects activating PIK3CA mutations in exons 9 and 20.
Polymerase Chain Reaction/Pyrosequencing
12-14 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
Tumor tissue.  
Specimen Preparation
Formalin fix (10 percent neutral buffered formalin) and paraffin embed tissue. Protect from excessive heat. Transport block or 5 unstained 5 micron slides. (Min: 3 slides) Transport block and/or slide(s) in a tissue transport kit (ARUP supply # 47808) available online through eSupply using ARUP Connect™or contact ARUP Client Services at (800) 522-2787.  
Storage/Transport Temperature
Room temperature or refrigerated. Ship in cooled container during summer months.  
Unacceptable Conditions
No tumor in tissue. Specimens fixed/processed in alternative fixatives (alcohol, Prefer®) or heavy metal fixatives (B-4 or B-5). Decalcified specimens.  
Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable  
Reference Interval
Interpretive Data
Refer to report.

Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
CPT Code(s)
88381; 81404
Component Test Code*Component Chart NameLOINC
2002148Block ID57723-9
2004511PIK3CA Results60034-6
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • anti-EGFR therapy resistance
  • PIK3
  • PIK3CA
  • PIK3CA exons 9, 20